Hosted on MSN
Daiichi Sankyo’s Promising Study on R-DXd for Resistant Ovarian Cancer: A Market Game-Changer?
Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results